As part of the U.S. Metabolic Conditions commercial organization, the SAM partners closely with Clinical Coordinators, Market Access, Medical Affairs, and Marketing to deliver an integrated customer experience and maximize outcomes across the treatment journey. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options.